Martindale December 2022 Update

This update contains 17 new monographs. Preparations have been updated for 5 countries.

New monographs:

• Belzutifan is a hypoxia-inducible factor 2 alpha inhibitor. It is used for the treatment of tumours associated with von Hippel-Lindau disease, such as renal cell carcinoma, central nervous system haemangioblastomas, and pancreatic neuroendocrine tumours.
• Capmatinib is a tyrosine kinase inhibitor that targets mesenchymal-epithelial transition factor (MET). It is used in the treatment of metastatic non-small cell lung cancer with MET exon 14 skipping alterations.
• Efgartigimod alfa is a human immunoglobulin G1 (IgG1) antibody fragment that binds to the neonatal Fc receptor (FcRn). It is used as an adjunct to standard therapy in the treatment of generalised myasthenia gravis in patients who are anti-acetylcholine receptor (AChR) antibody-positive. Efgartigimod alfa is also being investigated in the treatment of primary immune thrombocytopenia, pemphigus, and chronic inflammatory demyelinating polyneuropathy.
• Evinacumab is a human monoclonal antibody which inhibits angiopoietin-like 3 (ANGPTL3) and is used with other low-density lipoprotein (LDL) cholesterol lowering therapies for the treatment of homozygous familial hypercholesterolaemia.
• Finerenone is a nonsteroidal selective mineralocorticoid receptor antagonist used in the treatment of chronic kidney disease associated with type 2 diabetes.
• Imlifidase is an IgG-cleaving immunosuppressant that is used in highly sensitised, positive crossmatch kidney transplant patients to enable transplantation.
• Infigratinib is a tyrosine kinase inhibitor that is used in the treatment of FGFR2-positive cholangiocarcinoma.
• Isatuximab is a monoclonal antibody directed against CD38 that is used in the treatment of relapsed or refractory multiple myeloma. It is also under investigation for the first-line treatment of multiple myeloma.
• Lemborexant is an orexin-receptor antagonist used in the management of insomnia.
• Lurbinectedin is an antineoplastic alkylating agent, used in the treatment of metastatic small cell lung cancer.
• Ripretinib is a tyrosine kinase inhibitor used in the treatment of advanced gastrointestinal stromal tumours.
• Sacituzumab govitecan is an antibody-drug conjugate consisting of a Trop-2-directed monoclonal antibody conjugated to SN-38, a topoisomerase I inhibitor and the active metabolite of irinotecan. It is used for the treatment of locally advanced or metastatic triple-negative breast cancer and urothelial cancer.
• Samidorphan is an opioid antagonist used in a combination preparation with olanzapine for the treatment of schizophrenia and bipolar disorder.
• Selpercatinib is a tyrosine kinase inhibitor that is used in the treatment of non-small cell lung cancer and thyroid cancers.
• Sotorasib is a KRAS inhibitor used for the treatment of locally advanced or metastatic KRASG12C-mutated non-small cell lung cancer. It is also under investigation for the treatment of colorectal cancer and other solid tumours.
• Sutimlimab is a recombinant humanised monoclonal antibody that acts as a complement blocker by inhibiting the classical complement pathway at the C1s protein. It is used to reduce haemolysis in patients with cold haemagglutinin disease.
• Tafasitamab is a monoclonal antibody used in the treatment of diffuse large B-cell lymphoma (DLBCL).

Updated names, synonyms and codes; official standards; official preparations:

• BP 2021
• BP(Vet) 2021
• USP-NF 2022

Proprietary Preparations and Manufacturers updated for the following countries and regions:

• Canada
• France
• Germany
• Monaco
• Singapore
• Switzerland
• UK †
• USA †

† Countries updated on an ongoing basis